Handelsavisen
prelaunch
Companies Healthcare SIGC.NS
SI
SIGC.NS NSE (India) Pharmaceuticals

Sigachi Industries Ltd

$20,25
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,50 %
Op margin
12,3 %
ROE
3,5 %
Net margin
14,4 %
Debt / equity
0,35
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Sigachi Industries Ltd is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of pharmaceutical products.

Business. Sigachi Industries Ltd (SIGC.NS) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
3,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SIGC.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SIGC.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Sigachi Industries Ltd (SIGC.NS) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Sigachi Industries Ltd maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.35, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.67, suggesting it can cover its short-term obligations but with limited buffer. However, the company's net cash position is negative after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing.

    In terms of profitability, the company's return on equity (ROE) is 3.5%, and its return on assets (ROA) is 2.17%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that the company is not generating returns that are significantly above its cost of capital. The operating margin, calculated as operating income divided by revenue, is 12.33%, which is in line with the industry median of 12.5%.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The company's revenue concentration in a single segment also limits its ability to offset performance shortfalls in one area with gains in another.

    Looking ahead, the company's revenue is projected to grow by 4.5% in the current fiscal year and by 3.2% in the next fiscal year, based on the outlook provided in the financial data. This growth is modest and suggests a stable but not aggressive expansion strategy. The company's capital expenditures are negative, indicating that it is not investing in new assets and may be reducing its operational footprint or repaying debt.

    The risk assessment for Sigachi Industries Ltd highlights a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after accounting for total debt, which could necessitate additional financing in the near term. The dilution risk is low, as the number of shares outstanding has not changed between the basic and diluted counts, indicating no imminent threat from share issuance. The company has not disclosed any recent events such as major filings or transcripts that would suggest significant changes in its business strategy or financial position.

    The company's recent financial filings and disclosures do not indicate any major strategic shifts or operational disruptions. The absence of recent events suggests a stable but potentially stagnant business environment for Sigachi Industries Ltd.

    Key takeaways
    • Sigachi Industries Ltd has a moderate debt-to-equity ratio of 0.35, indicating a balanced capital structure.
    • The company's ROE of 3.5% and ROA of 2.17% are below the industry median, suggesting suboptimal returns on invested capital.
    • Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
    • The company's projected revenue growth is modest, with a 4.5% increase expected in the current fiscal year.
    • The company faces medium liquidity risk due to a negative net cash position after subtracting total debt.
    • The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted counts.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Revenue grew at a 26.2% CAGR over four years, demonstrating strong top-line expansion momentum.

    Net income expanded at a 23.1% CAGR, indicating consistent profitability growth alongside revenue increases.

    Free cash flow surged 296.9% year-over-year, highlighting a significant improvement in cash generation capabilities.

    BEAR CASE · 4

    High credit risk flags suggest potential vulnerabilities in the company's ability to meet financial obligations.

    Debt-to-equity ratio of 0.35 is below the cohort median, suggesting higher leverage relative to peers.

    Cash conversion ratio of 0.86 trails the 0.95 cohort median, indicating weaker cash flow quality.

    Medium liquidity risk flags indicate potential challenges in meeting short-term financial obligations promptly.

    In focus — financials by report

    Valuation FY

    Market price
    $20,25
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $4.30B
    Net cash
    -$1.51B
    Current ratio
    1.7
    Debt / equity
    0.3
    ROA
    2.2%
    ROE
    3.5%
    Cash conversion
    86.0%
    CapEx / revenue
    -81.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin12,3 %Above median
    Net Margin14,4 %Above P75
    ROE3,5 %Above median
    Capex / Rev-81,8 %Bottom quartile
    D/E0,35Below median
    Cash Conv0,86Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Sigachi Industries Ltd Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SIGC.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage